<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04246034</url>
  </required_header>
  <id_info>
    <org_study_id>VLNT for lymphedema</org_study_id>
    <nct_id>NCT04246034</nct_id>
  </id_info>
  <brief_title>Microvascular Breast Reconstruction With Lymph Node Transfer</brief_title>
  <official_title>Evaluation of Outcomes of Microvascular Breast Reconstruction With Lymph Node Transfer for Postmastectomy Lymphedema Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      this study aims to evaluate the outcomes of simultaneous free abdominal flap &amp; vascularized
      lymph node transfer for both breast reconstruction and postmastectomy lymphedema
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Microvascular breast reconstruction allows for the transfer of donor tissue that is an
      excellent match for native breast tissue, both in terms of the subcutaneous tissue that
      reconstitutes the breast mound and the simultaneous transfer of skin. In addition, it offers
      a wide range of options for women who may have been previously not considered for autologous
      tissue transfer. From the these various options, the deep inferior epigastric artery
      perforator (DIEP) flap and the muscle-sparing transverse rectus abdominis myocutaneous
      (MS-TRAM) flap are the most recognized free flap options for breast reconstruction today

      Besides the needs for breast reconstruction after mastectomy &amp; axillary lymph node
      dissection, upper limb lymphedema is also a major concern for postmastectomy patients which
      is estimated to occur in 21.4% of women treated for breast cancer. It represents a diagnostic
      and therapeutic challenge for clinicians due to the heterogeneity in presentation as well as
      multitude of treatment options available. In addition, with a lack of evidence-based
      guidelines

      . According to the International Society of Lymphology Consensus, the clinical staging of
      lymphedema includes; Stage 0 (Subclinical) when lymphatic vessels have been injured but have
      no measurable swelling or edema. Stage I lymphedema occurs with the onset of measurable
      swelling and pitting of the skin which can be regressed on conservative treatments. Stage II
      considered when there is edema partially regressing with treatments and negative pitting
      test. Stage III encompasses lymphostatic elephantiasis with trophic skin changes and
      recurrent infections.

      In recent years, lymphatic microsurgery procedures have increased in popularity, bringing in
      a new wave of physiologic surgical options for the management of lymphedema. The two most
      common microsurgical options include lymphovenous anastomosis (LVA) and vascularized lymph
      node transfer (VLNT). Each treatment option has the potential to bypass areas of damaged
      lymphatics by rerouting the lymph into the venous system or by replacing the lost lymph nodes
      and, or lymphatic ducts.

      Recent studies have evaluated the positive effects of VLNT in the setting of lymphedema and
      have shown significantly better results for the patients in which the native lymphatic ducts
      are no longer available when compared to conservative treatments or LVA.

      There are several potential donor sites that can be used for the VLNT, and currently, there
      is no clear consensus as to which lymph node basin represents the ideal donor site. But the
      most popular lymph nodes have been the supraclavicular nodes, the submental nodes, the
      lateral thoracic nodes, the inguinal nodes, the omentum, and more recently the mesenteric
      lymph nodes. However, in patients suffering from post-mastectomy lymphedema, the inguinal
      nodes can be transferred at the time of autologous breast reconstruction, coupling the
      inguinal nodes to (DIEP) flap or (MS-TRAM) flap to reconstruct the patient's breast while
      simultaneously addressing the patient's lymphedema in one operation .

      Advantages of simultaneous breast reconstruction &amp; VLNT include the extensive scar removal
      and release in the axilla, which is critical to optimizing the recipient bed for the VLNT and
      the relatively hidden scar in axilla. Although a promising technique, it remains
      investigational and requires larger studies with longer follow-up to validate its true
      utility. Of primary concern is monitoring for the longevity of the results and making certain
      that additional donor site morbidity is avoided.

      To the best of the investigator's knowledge, few studies were conducted on the use of free
      abdominal free flaps in conjunction with VLNT from the groin for simultaneous lymphedema
      treatment &amp; breast reconstruction. But these studies were limited by small sample sizes.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2021</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in upper limb volume</measure>
    <time_frame>6-12 months</time_frame>
    <description>Assessment of volume reduction by measuring limb circumference of affected and non affected upper limbs at fixed points from shoulder, elbow &amp; wrist joints</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in lymphatic flow</measure>
    <time_frame>6-12 months</time_frame>
    <description>lymphoscintigraphy will be used to trace radiological signs of Lymphatic flow improvement such as reduced dermal backflow, appearance of new lymph drainage channels, reduced stasis and increased rate of radiolabeled tracer clearance</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life measure for limb lymphedema (LYMQOL)</measure>
    <time_frame>6-12 months</time_frame>
    <description>Quality of life parameters will be measured using LYMQOL survey. Questions in the survey cover four areas: symptoms, body image/appearance, function and mood. Answers are scored 1-4 (less severe to severe)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life measure for breast</measure>
    <time_frame>6-12 months</time_frame>
    <description>patient quality of life will be evaluated using Breast-Q &quot;Reconstruction Module&quot;, which includes different modules for assessment of quality of life and patient satisfaction after breast reconstruction. These scales are designed to be administered pre-operatively and assess patient expectations for the process and outcome of surgery. The expectations scales compliment the satisfaction and quality-of life domains of the postoperative reconstruction module. Multi-item and categorical scale structures are used. Five scales provide a 0-100 score. A higher score means better quality of life and more satisfaction.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Lymphedema</condition>
  <condition>Lymphedema of Upper Arm</condition>
  <condition>Mastectomy; Lymphedema</condition>
  <arm_group>
    <arm_group_label>Cases</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>As described by Saaristo et al. in 2012, the surgical technique starts with wide axillary scar removal, followed by elevation of contralateral dual flap which includes DIEP/MS-TRAM with attached groin lymph nodes and fat, then the anastomosis is preferably done to internal mammary vessels.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Microvascular Breast Reconstruction with Vascularized Lymph Node Transfer</intervention_name>
    <description>simultaneous free abdominal flaps with VLNT from groin are transferred on a single pedicle for breast reconstruction and postmastectomy lymphedema</description>
    <arm_group_label>Cases</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female patients of 20-65 years old

          -  Patients seeking autologous breast reconstruction and complain of clinically diagnosed
             arm lymphedema

          -  Deficient lymphatic drainage on lymphoscintigraphy

          -  Stage II and III Lymphedema

          -  no active cellulitis

          -  more than 12 months of follow-up

        Exclusion Criteria:

          -  Females &lt; 20 or &gt;65 years old

          -  distant metastasis

          -  brachial plexus neuritis.

          -  Patients with unhealthy and obstructed recipient veins or congestive heart disease
             with limited venous return may not be a suitable candidate for the procedure.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>as the scope of study is breast cancer, participant should be of female gender</gender_description>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Youssef S Hassan, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Assiut University Hospitals - Plastic Surgery Dept.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Haitham Khalil, MD, FRCS</last_name>
    <role>Study Director</role>
    <affiliation>Divison of Plastic and Reconstructive Surgery (University Hospitals Birmingham)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Awny M Asklany, MD</last_name>
    <role>Study Director</role>
    <affiliation>Assiut University Hospitals - Plastic Surgery Dept.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ahmed S Sharaf, Msc</last_name>
    <phone>1090619155</phone>
    <phone_ext>+20</phone_ext>
    <email>ahmed.sharaf90@aun.edu.eg</email>
  </overall_contact>
  <reference>
    <citation>Saaristo AM, Niemi TS, Viitanen TP, Tervala TV, Hartiala P, Suominen EA. Microvascular breast reconstruction and lymph node transfer for postmastectomy lymphedema patients. Ann Surg. 2012 Mar;255(3):468-73. doi: 10.1097/SLA.0b013e3182426757.</citation>
    <PMID>22233832</PMID>
  </reference>
  <reference>
    <citation>DiSipio T, Rye S, Newman B, Hayes S. Incidence of unilateral arm lymphoedema after breast cancer: a systematic review and meta-analysis. Lancet Oncol. 2013 May;14(6):500-15. doi: 10.1016/S1470-2045(13)70076-7. Epub 2013 Mar 27. Review.</citation>
    <PMID>23540561</PMID>
  </reference>
  <reference>
    <citation>Smile TD, Tendulkar R, Schwarz G, Arthur D, Grobmyer S, Valente S, Vicini F, Shah C. A Review of Treatment for Breast Cancer-Related Lymphedema: Paradigms for Clinical Practice. Am J Clin Oncol. 2018 Feb;41(2):178-190. doi: 10.1097/COC.0000000000000355.</citation>
    <PMID>28009597</PMID>
  </reference>
  <reference>
    <citation>Executive Committee. The Diagnosis and Treatment of Peripheral Lymphedema: 2016 Consensus Document of the International Society of Lymphology. Lymphology. 2016 Dec;49(4):170-84.</citation>
    <PMID>29908550</PMID>
  </reference>
  <reference>
    <citation>Pappalardo M, Patel K, Cheng MH. Vascularized lymph node transfer for treatment of extremity lymphedema: An overview of current controversies regarding donor sites, recipient sites and outcomes. J Surg Oncol. 2018 Jun;117(7):1420-1431. doi: 10.1002/jso.25034. Epub 2018 Mar 24. Review.</citation>
    <PMID>29572824</PMID>
  </reference>
  <reference>
    <citation>Engel H, Lin CY, Huang JJ, Cheng MH. Outcomes of Lymphedema Microsurgery for Breast Cancer-related Lymphedema With or Without Microvascular Breast Reconstruction. Ann Surg. 2018 Dec;268(6):1076-1083. doi: 10.1097/SLA.0000000000002322.</citation>
    <PMID>28594742</PMID>
  </reference>
  <reference>
    <citation>Chang EI, Masi√† J, Smith ML. Combining Autologous Breast Reconstruction and Vascularized Lymph Node Transfer. Semin Plast Surg. 2018 Feb;32(1):36-41. doi: 10.1055/s-0038-1632402. Epub 2018 Apr 9. Review.</citation>
    <PMID>29636652</PMID>
  </reference>
  <reference>
    <citation>Nguyen AT, Chang EI, Suami H, Chang DW. An algorithmic approach to simultaneous vascularized lymph node transfer with microvascular breast reconstruction. Ann Surg Oncol. 2015 Sep;22(9):2919-24. doi: 10.1245/s10434-015-4408-4. Epub 2015 Jan 27.</citation>
    <PMID>25623599</PMID>
  </reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>January 18, 2020</study_first_submitted>
  <study_first_submitted_qc>January 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 29, 2020</study_first_posted>
  <last_update_submitted>April 22, 2020</last_update_submitted>
  <last_update_submitted_qc>April 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Ahmed ElSayed Sharaf Ahmed</investigator_full_name>
    <investigator_title>Assistant Lecturer</investigator_title>
  </responsible_party>
  <keyword>VLNT</keyword>
  <keyword>breast reconstruction</keyword>
  <keyword>postmastectomy lymphedema</keyword>
  <keyword>vascularized lymph node transfer</keyword>
  <keyword>lymphedema surgery</keyword>
  <keyword>microsurgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphedema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

